We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TT-00420

News List

TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma prnasia
November 04, 2021
TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule drug therapies for oncology, inflammatory and cardiovascular diseases...
TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China prnasia
May 27, 2021
TransThera Biosciences Co. Ltd. announced that it has entered into a collaboration agreement with Roche to explore the combination of TT-00420 and atezolizumab for the treatment of patients in China with gastrointestinal ("GI") tract cancers.